These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23256738)

  • 21. Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model.
    Barman S; Koley H; Ramamurthy T; Chakrabarti MK; Shinoda S; Nair GB; Takeda Y
    Microbiol Immunol; 2013 Nov; 57(11):762-71. PubMed ID: 24033533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination vaccine strategies to prevent enteric infections.
    Walker R; Dull P
    Vaccine; 2017 Dec; 35(49 Pt A):6790-6792. PubMed ID: 28705515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice.
    Barman S; Koley H; Nag D; Shinoda S; Nair GB; Takeda Y
    Microbiol Immunol; 2014 Aug; 58(8):463-6. PubMed ID: 24909404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum IgG antibodies to
    Cohen D; Meron-Sudai S; Bialik A; Asato V; Goren S; Ariel-Cohen O; Reizis A; Hochberg A; Ashkenazi S
    Hum Vaccin Immunother; 2019; 15(6):1401-1408. PubMed ID: 31070988
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Willingness to be vaccinated against shigella and other forms of dysentery: a comparison of three regions in Asia.
    Pack R; Wang Y; Singh A; von Seidlein L; Pach A; Kaljee L; Butraporn P; Youlong G; Blum L; Bhutta Z; Santoso SS; Trach DD; Waluyo I; Nyamete A; Clemens J; Stanton B
    Vaccine; 2006 Jan; 24(4):485-94. PubMed ID: 16137802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice.
    Camacho AI; de Souza J; Sánchez-Gómez S; Pardo-Ros M; Irache JM; Gamazo C
    Vaccine; 2011 Oct; 29(46):8222-9. PubMed ID: 21911022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shigella Vaccine Development: Finding the Path of Least Resistance.
    Chen WH; Kotloff KL
    Clin Vaccine Immunol; 2016 Dec; 23(12):904-907. PubMed ID: 27707764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV; Roberts F; Verma NK
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classical and novel strategies to develop a
    Barel LA; Mulard LA
    Hum Vaccin Immunother; 2019; 15(6):1338-1356. PubMed ID: 31158047
    [No Abstract]   [Full Text] [Related]  

  • 33. An Approach to Identify and Characterize a Subunit Candidate Shigella Vaccine Antigen.
    Pore D; Chakrabarti MK
    Methods Mol Biol; 2016; 1403():433-44. PubMed ID: 27076146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on Shigella vaccines.
    Ashkenazi S; Cohen D
    Isr J Med Sci; 1994; 30(5-6):495-7. PubMed ID: 8034510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains.
    Mel D; Gangarosa EJ; Radovanovic ML; Arsic BL; Litvinjenko S
    Bull World Health Organ; 1971; 45(4):457-64. PubMed ID: 4948417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High vaccine efficacy against shigellosis of recombinant noninvasive Shigella mutant that expresses Yersinia invasin.
    Suzuki T; Yoshikawa Y; Ashida H; Iwai H; Toyotome T; Matsui H; Sasakawa C
    J Immunol; 2006 Oct; 177(7):4709-17. PubMed ID: 16982910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome.
    Behar A; Fookes MC; Goren S; Thomson NR; Cohen D
    Vaccine; 2015 Jun; 33(26):2978-83. PubMed ID: 25936664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
    Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
    Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Shigella human challenge model.
    Porter CK; Thura N; Ranallo RT; Riddle MS
    Epidemiol Infect; 2013 Feb; 141(2):223-32. PubMed ID: 22906296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The health belief model and factors relating to potential use of a vaccine for shigellosis in Kaeng Koi district, Saraburi province, Thailand.
    Butraporn P; Pach A; Pack RP; Masngarmmeung R; Maton T; Sri-aroon P; Nyamete A; Chaicumpa W
    J Health Popul Nutr; 2004 Jun; 22(2):170-81. PubMed ID: 15473520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.